Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. [electronic resource]
Producer: 20190617Description: 1315-1327 p. digitalISSN:- 1474-5488
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzimidazoles -- administration & dosage
- Biomarkers, Tumor -- genetics
- Carbamates -- administration & dosage
- Disease Progression
- Female
- Genetic Predisposition to Disease
- Humans
- Male
- Melanoma -- drug therapy
- Middle Aged
- Mutation
- Phenotype
- Progression-Free Survival
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins B-raf -- genetics
- Skin Neoplasms -- drug therapy
- Sulfonamides -- administration & dosage
- Time Factors
- Vemurafenib -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.